A provider-focused briefing on the Myfortic shortage in 2026: supply timeline, prescribing implications, alternatives, cost access tools, and resources.
If your transplant patients are reporting difficulty filling their Myfortic (Mycophenolic Acid) prescriptions, they're not exaggerating. Generic Mycophenolate Sodium delayed-release tablets have been subject to intermittent supply disruptions, and while brand-name Myfortic from Novartis has generally remained available, the practical reality for patients at the pharmacy counter is more complicated.
This article provides a concise but thorough overview of the current Myfortic supply landscape — what's driving the shortage, how it affects prescribing decisions, and what tools are available to help you and your patients navigate it.
Myfortic (Mycophenolate Sodium delayed-release tablets) was FDA-approved in February 2004 and has been a mainstay in kidney transplant immunosuppression protocols since then. Generic versions became available after patent expiration, with manufacturers including Mylan (Viatris) entering the market.
Over the past several years, the ASHP Drug Shortage Resource Center has listed Mycophenolate Sodium delayed-release tablets as experiencing supply constraints. The pattern has been intermittent rather than continuous — periods of normal supply punctuated by weeks or months where one or more generic manufacturers cannot meet demand.
Key timeline factors:
The intermittent nature of this shortage creates several clinical challenges:
Novartis has maintained production of brand-name Myfortic (180 mg and 360 mg delayed-release tablets). However, most patients are dispensed the generic due to cost and formulary requirements. When the generic is unavailable, patients face a choice between an expensive brand-name fill or going without — neither is acceptable for transplant immunosuppression.
If converting a patient from Myfortic to CellCept (Mycophenolate Mofetil) due to availability, the recommended equivalency is:
Note that Myfortic and CellCept are not interchangeable on a milligram-for-milligram basis. The enteric-coated formulation of Myfortic also results in different absorption kinetics. Monitor MPA trough levels after any switch, particularly in the first 2–4 weeks.
Patients who were originally switched from CellCept to Myfortic due to GI adverse effects may experience recurrence of symptoms if converted back. The enteric coating of Myfortic delays drug release to the small intestine, reducing upper GI exposure. Document the original reason for the Myfortic preference so it can be communicated during any formulary exception or prior authorization request.
As of early 2026:
Availability can differ significantly by geography and pharmacy type. Specialty pharmacies affiliated with transplant centers tend to have more reliable supply than retail chain pharmacies.
The cost differential between brand and generic creates a significant access barrier:
Insurance complications compound the problem. Many plans require prior authorization for Myfortic, and some mandate step therapy through Mycophenolate Mofetil before approving Mycophenolic Acid. When a patient needs the specific enteric-coated formulation for GI tolerability, these requirements can delay access.
Medfinder for Providers allows you and your staff to check real-time pharmacy availability of Myfortic and its generics. This can be integrated into your clinic workflow when patients report difficulty filling their prescriptions. Rather than spending staff time on phone calls to pharmacies, you can direct patients to a pharmacy with confirmed stock.
Novartis offers the SaveOnMyPrescription.com program for Myfortic. Patients with any payer type — including Medicare, Medicaid, commercial insurance, and uninsured — can check eligibility. This is particularly relevant when patients must fill brand-name Myfortic due to generic unavailability.
If a patient's plan requires step therapy through CellCept, but the patient has documented GI intolerance or other clinical reasons for Myfortic, a formulary exception letter detailing the medical necessity can expedite approval. Include:
For uninsured or underinsured patients, the Novartis Patient Assistance Foundation provides free medication to qualifying patients. Applications are available at patient.novartis.com or by calling 1-800-277-2254. Additional resources include NeedyMeds.org and RxAssist.org.
When Myfortic is unavailable, the following agents may be appropriate depending on the clinical scenario:
For patient-facing information on alternatives: Alternatives to Myfortic If You Can't Fill Your Prescription.
The fundamental drivers of this shortage — limited generic manufacturers, rising transplant volumes, and supply chain fragility — are not expected to resolve quickly. Providers should:
Medication access is a clinical issue, not just an administrative one. When a transplant patient can't fill their Myfortic prescription, the risk isn't theoretical — it's a real threat to graft survival. By staying informed about the supply landscape, having conversion protocols ready, and using available tools, providers can minimize the impact of these disruptions on patient outcomes.
Related provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
